Target intelligence / Profile preview

Copper ion (extracellular and mitochondrial pool) (Cu)

Target
Cu
Molecular classification
Metal ion, Cofactor
01

Overview

Copper ions in the extracellular and mitochondrial pools are essential trace elements that function as critical cofactors for a variety of enzymes, including cytochrome c oxidase and superoxide dismutase (Ruiz et al., 2021, Nature Reviews Molecular Cell Biology). These ions play a fundamental role in mitochondrial respiration, antioxidant defense, and the regulation of cell signaling pathways. Dysregulation of copper homeostasis, characterized by either deficiency or toxic accumulation, is central to the pathogenesis of Wilson's disease, Menkes disease, and various cancers (National Institutes of Health, 2021). In oncology, targeting the mitochondrial copper pool has emerged as a novel strategy to induce cuproptosis, a copper-dependent form of regulated cell death (Tsvetkov et al., 2022, Science). Therapeutic interventions typically utilize chelating agents to reduce systemic copper levels or ionophores to selectively increase copper concentrations within specific cellular compartments to achieve a therapeutic effect.

Other names
CopperCupric ionCuprous ionLabile copper poolMitochondrial copperExtracellular copper
02

Mechanism of action

Drugs targeting copper ions primarily act through chelation, where they bind to extracellular or intracellular copper to facilitate its excretion, thereby reducing systemic toxicity (Roberts & Schilsky, 2008, Hepatology). Alternatively, copper ionophores like elesclomol transport copper into the mitochondria, where an accumulation of copper leads to the aggregation of lipoylated proteins in the TCA cycle, triggering a unique form of cell death known as cuproptosis (Tsvetkov et al., 2022, Science). Zinc-based therapies work indirectly by inducing intestinal metallothionein, which traps dietary copper and prevents its absorption into the systemic pool.

03

Biological functions

Mitochondrial respirationRedox signalingEnzyme cofactorAngiogenesisOxidative phosphorylationIron homeostasis
04

Disease associations

Wilson's diseaseMenkes diseaseCancerAlzheimer's diseaseParkinson's diseaseAmyotrophic lateral sclerosis
05

Safety considerations

Copper deficiencySideroblastic anemiaNeutropeniaNeurological worsening during initial treatmentNephrotoxicityTeratogenicity
06

Interacting drugs

Penicillamine

5 more in the full profile.

07

Biomarkers

Serum free copperCeruloplasmin24-hour urinary copper excretionHepatic copper concentrationFDX1 expressionLIAS expression

Beyond the preview

Go deeper on Copper ion (extracellular and mitochondrial pool) (Cu).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Copper ion (extracellular and mitochondrial pool) (Cu).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call